A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.
Yan Zhang, Ye-Fan Hu, Lingyu Ma...
https://pubmed.ncbi.nlm.nih.gov/40918097/Actively Recruiting
Led by The University of Hong Kong-Shenzhen Hospital · Updated on 2025-03-25
154
Participants Needed
2
Research Sites
2 weeks
Total Duration
Researchers are evaluating an individualized tumor neoantigen peptide vaccine combined with radiotherapy in patients with advanced malignant solid tumors that have not responded to standard treatments or have progressed. This Phase II randomized study aims to observe tumor burden after treatment, immune responses triggered by the vaccine, and overall patient survival to assess the vaccines safety and effectiveness alongside radiotherapy. The treatment involves collecting tumor tissue surgically or by biopsy and blood samples to analyze tumor gene mutations and confirm mutation expression. Using advanced sequencing and software analysis, personalized neoantigen peptides are identified and synthesized into a vaccine. Participants first receive precise radiotherapy, followed one week later by the peptide vaccine treatment lasting up to five months. The study includes two groups one receiving the personalized vaccine plus conventional radiotherapy and the other receiving placebo plus conventional radiotherapy. Participants will undergo assessments including imaging to measure tumor lesions and monitor progression-free survival at the end of each treatment course and at several intervals up to four months after treatment completion. Safety, feasibility, and immune response are evaluated throughout. Eligibility involves meeting criteria related to tumor status, survival expectancy, and ability to provide tumor DNA samples. The total study duration includes treatment and follow-up visits to track outcomes and patient health.
CONDITIONS
Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
F
Feng-Ming (Spring) Kong
Y
Yan Zhang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The University of Hong Kong-Shenzhen Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - 5 months
Participants first receive precision radiotherapy treatment, followed by individualized tumor neoantigen peptide vaccine treatment.
Visits conducted at the end (or termination) of each treatment course
Duration - 4 months
Participants are monitored for progression-free survival after treatment completion.
Visits at 30, 90, and 120 days after the end of the last treatment course
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yan Zhang, Ye-Fan Hu, Lingyu Ma...
https://pubmed.ncbi.nlm.nih.gov/40918097/The University of Hong Kong-Shenzhen Hospital
Lead Sponsor